Nerve growth factor (NGF) is a neurotrophic factor known to affect the survival and differentiation of neuroblasts and some neuroblastoma cell lines. The effects of NGF are mediated through a cell surface receptor which has recently been characterized and cloned in our laboratory. Our first Specific Aim is to survey freshly excised neuroblastomas, neuroblastomas placed into short- term culture, and neuroblastoma cell lines for expression of NGF receptor, the affinity and characteristics of the NGF receptor, and the responsiveness of the neuroblastomas to NGF. We will analyze the NGF receptor for these neuroblastomas by immunoperoxidase staining with monoclonal anti-NGF receptor antibodies, by Western blotting and 125I-NGF binding. Differentiation of neuroblastomas will be determined by morphology, 3H-thymidine incorporation, enzyme activities, and Northern blotting. We will correlate these results with the stage of the disease, the clinical prognosis, and the subclass of neuroblastoma. Our second Specific Aim is to determine whether H-myc oncogene which is amplified in about 50% of advanced neuroblastomas alters the expression and molecular characteristics of the NGF receptor and the ability of these cells to respond to NGF. Neuroblastoma cell lines that do not express H-myc will be compared with those that do and with neuroblastoma cell lines that express N-myc as a result of transfection with N- myc oncogene. Our third Specific Aim is to restore expression of NGF receptor in those cell lines which lack the receptor and lo assess whether restored expression results in NGF-inducible differentiation. Expression of NGF receptor will be induced by transfection or with a retrovirus bearing the NGF receptor cDNA. The results of these experiments should provide insight into the mechanism by which activation of oncogenes blocks differentiation in neuroblastoma, and into therapeutic approaches for this disease and other malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA047983-01
Application #
3821207
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Moshier, J A; Skunca, M; Wu, W et al. (1996) Regulation of ornithine decarboxylase gene expression by the Wilms' tumor suppressor WT1. Nucleic Acids Res 24:1149-57
Fredericks, W J; Galili, N; Mukhopadhyay, S et al. (1995) The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 15:1522-35
Amin, K M; Litzky, L A; Smythe, W R et al. (1995) Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 146:344-56
Werner, H; Shen-Orr, Z; Rauscher 3rd, F J et al. (1995) Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol 15:3516-22
Hol, F A; Hamel, B C; Geurds, M P et al. (1995) A frameshift mutation in the gene for PAX3 in a girl with spina bifida and mild signs of Waardenburg syndrome. J Med Genet 32:52-6
Macina, R A; Barr, F G; Galili, N et al. (1995) Genomic organization of the human PAX3 gene: DNA sequence analysis of the region disrupted in alveolar rhabdomyosarcoma. Genomics 26:1-8
Ryan, G; Steele-Perkins, V; Morris, J F et al. (1995) Repression of Pax-2 by WT1 during normal kidney development. Development 121:867-75
Morris, J F; Rauscher 3rd, F J; Davis, B et al. (1995) The myeloid zinc finger gene, MZF-1, regulates the CD34 promoter in vitro. Blood 86:3640-7
Barr, F G; Chatten, J; D'Cruz, C M et al. (1995) Molecular assays for chromosomal translocations in the diagnosis of pediatric soft tissue sarcomas. JAMA 273:553-7
Bennicelli, J L; Fredericks, W J; Wilson, R B et al. (1995) Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. Oncogene 11:119-30

Showing the most recent 10 out of 75 publications